Cargando…
Progesterone in gender-affirming therapy of trans women
Progesterone is an endogenous steroid hormone with an important role for the physiology of the female reproductive system and the mammary gland. It has additional significant actions in other tissues, such as the cardiovascular system, the central nervous system, and bones. The present article explo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558402/ https://www.ncbi.nlm.nih.gov/pubmed/35721880 http://dx.doi.org/10.4331/wjbc.v13.i3.66 |
_version_ | 1785117267372015616 |
---|---|
author | Milionis, Charalampos Ilias, Ioannis Koukkou, Eftychia |
author_facet | Milionis, Charalampos Ilias, Ioannis Koukkou, Eftychia |
author_sort | Milionis, Charalampos |
collection | PubMed |
description | Progesterone is an endogenous steroid hormone with an important role for the physiology of the female reproductive system and the mammary gland. It has additional significant actions in other tissues, such as the cardiovascular system, the central nervous system, and bones. The present article explores potential clinical implications from the addition of bioidentical progesterone to gender-affirming treatment of trans women. For this purpose, it provides an overview of the physiological action of progesterone in target tissues and speculates on possible benefits for gender transitioning. Progesterone is expected to exert moderate anti-androgen action through suppression of the hypothalamic-pituitary-gonadal axis and inhibition of the conversion of testosterone to dihydrotestosterone. It may also contribute to breast maturation. In the long-term, progesterone could prevent bone loss and protect cardiovascular health. The potential benefits are mainly inferred by extrapolating evidence from biological actions in cisgender women and medical assumptions and hence, clinicians need to be cautious when applying these data into practice. Further research is needed to ascertain the efficacy and safety of progesterone in current hormonal regimens. |
format | Online Article Text |
id | pubmed-10558402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-105584022023-10-08 Progesterone in gender-affirming therapy of trans women Milionis, Charalampos Ilias, Ioannis Koukkou, Eftychia World J Biol Chem Minireviews Progesterone is an endogenous steroid hormone with an important role for the physiology of the female reproductive system and the mammary gland. It has additional significant actions in other tissues, such as the cardiovascular system, the central nervous system, and bones. The present article explores potential clinical implications from the addition of bioidentical progesterone to gender-affirming treatment of trans women. For this purpose, it provides an overview of the physiological action of progesterone in target tissues and speculates on possible benefits for gender transitioning. Progesterone is expected to exert moderate anti-androgen action through suppression of the hypothalamic-pituitary-gonadal axis and inhibition of the conversion of testosterone to dihydrotestosterone. It may also contribute to breast maturation. In the long-term, progesterone could prevent bone loss and protect cardiovascular health. The potential benefits are mainly inferred by extrapolating evidence from biological actions in cisgender women and medical assumptions and hence, clinicians need to be cautious when applying these data into practice. Further research is needed to ascertain the efficacy and safety of progesterone in current hormonal regimens. Baishideng Publishing Group Inc 2022-05-27 2022-05-27 /pmc/articles/PMC10558402/ /pubmed/35721880 http://dx.doi.org/10.4331/wjbc.v13.i3.66 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Milionis, Charalampos Ilias, Ioannis Koukkou, Eftychia Progesterone in gender-affirming therapy of trans women |
title | Progesterone in gender-affirming therapy of trans women |
title_full | Progesterone in gender-affirming therapy of trans women |
title_fullStr | Progesterone in gender-affirming therapy of trans women |
title_full_unstemmed | Progesterone in gender-affirming therapy of trans women |
title_short | Progesterone in gender-affirming therapy of trans women |
title_sort | progesterone in gender-affirming therapy of trans women |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558402/ https://www.ncbi.nlm.nih.gov/pubmed/35721880 http://dx.doi.org/10.4331/wjbc.v13.i3.66 |
work_keys_str_mv | AT milionischaralampos progesteroneingenderaffirmingtherapyoftranswomen AT iliasioannis progesteroneingenderaffirmingtherapyoftranswomen AT koukkoueftychia progesteroneingenderaffirmingtherapyoftranswomen |